Market capitalization | $25.48m |
Enterprise Value | $21.41m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.88 |
P/S ratio (TTM) P/S ratio | 1.04 |
P/B ratio (TTM) P/B ratio | 5.28 |
Revenue growth (TTM) Revenue growth | 271.49% |
Revenue (TTM) Revenue | $24.39m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
Jun '24 |
+/-
%
|
||
Revenue | 24 24 |
271%
271%
|
|
Gross Profit | 22 22 |
-
|
|
EBITDA | -2.74 -2.74 |
40%
40%
|
EBIT (Operating Income) EBIT | -2.78 -2.78 |
40%
40%
|
Net Profit | -4.34 -4.34 |
37%
37%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
InnoCan Pharma Corp. operates as a pharmaceutical tech company. Its segments include: Pharmaceuticals and Consumer Wellness. The Pharmaceuticals segment focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science. It involves two drug delivery technologies: LPT CBD- loaded liposome platform and CLX CBD-loaded exosomes platform. The Consumer Wellness segment develops and markets a wide portfolio of innovative and self-care products to promote a healthier lifestyle. The company was founded in October 2017 and is headquartered in Alberta, Canada.
Head office | Canada |
CEO | Iris Bincovich |
Employees | 9 |
Founded | 2018 |
Website | www.innocanpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.